News Release
January 15, 2016

Finding the Needle in a Microbial Haystack: Penn Researchers Test New Pathogen Detection Technology

PHILADELPHIA - Patients who are undergoing treatment for diseases such as cancer often face the added challenge of a compromised immune system, which can be a toll both of their condition and the drugs used to treat it, leaving them vulnerable to various opportunistic infections. Many of these infections are not only life-threatening, but caused by rare organisms that are extremely difficult to isolate and identify. However, the sooner an infection is pinned down, the faster and more effectively it can be treated. After developing a novel investigational technology called PathoChip that can rapidly identify elusive microorganisms, a team of Penn Medicine researchers recently succeeded for the first time in identifying a pathogen in a patient sample, demonstrating the proof of principle that this technology can be used to identify pathogens in human disease.

In a recently published study in Cancer Biology & Therapy, the group of Penn colleagues, led by Erle Robertson, PhD, professor and vice-chair  for research in Otorhinolaryngology at the Perelman School of Medicine, and James Alwine, PhD, a professor of Cancer Biology and Michael Feldman, MD, a professor of Pathology and Laboratory Medicine, used a version of the PathoChip microarray, which contains 60,000 probes for all known viruses, as well as a broad range of bacteria, protozoa, fungi, and helminthes, a parasitic worm, to identify the pathogenic agent in the sample of a patient. They analyzed preserved tissue samples from a middle-aged male with relapsed acute myelogenous leukemia (AML) who developed an unknown fungal infection following chemotherapy.

“We've run many tests to see if we could identify pathogens in the lab, just to see if the PathoChip has efficacy in identifying a variety of organisms, and we were able to identify all infectious agents tested, ”Robertson said. “But this was the first time we actually looked directly at a patient sample to identify a pathogenic agent.”

The PathoChip allows for a single sample to be tested simultaneously for thousands of possibilities, dramatically reducing the time required for diagnosis. They first screened the sample and analyzed it with a type of bioinformatics probe to narrow the focus to a specific microbial family. Seventeen organisms displaying the highest signal were compared with the signals from a control sample. Molecular signals obtained from additional bioinformatics tests provided further information, which led to the identification of the specific infectious agent-- in this case one of the two species of Rhizomucor, a rare fungus known to cause zygomycosis in humans.

A potentially fatal illness most often seen in immunocompromised patients, zygomycosis is not only difficult to treat but challenging to diagnose. Fungal species can be painfully slow or even impossible to culture in the laboratory, delaying or preventing their identification and therefore patient treatment. As Robertson explains, the PathoChip provides an efficient alternative. “With this technology, out of 60,000 possibilities and probes that we used, in a little over 24 hours we were able to identify this particular fungi," he says. 

While other techniques, such as sequencing arrays, are available to identify unknown infectious organisms, these approaches can also have significant limitations. “You could use other technologies such as next-generation sequencing, but there would have to be a high percentage of nucleic acids present in the tissue, and technicians would need enough of these materials to do the sequencing,” Robertson explains.

“The analysis component of it would take more time,” he adds. “We think this technology is complementary to next-generation sequencing in some ways, and even more finely tuned, because we have a much higher sensitivity in detecting agents or individual organisms present in any kind of sample, whether it's abiotic or biotic. We can identify agents in soil, for example, in plant tissue, in animal tissue, or human tissue.”

Robertson and his team in the laboratory, which includes Sagarika Banerjee, PhD, and research technician Kristen Peck, M.Sc. along with bioinformatics expert Zhi Wei, Ph.D. from the New Jersey Science and Technology Institute, are looking ahead to both expanding the capabilities of the PathoChip and increasing its use in the clinic: “We are constantly updating it based on what we think are important agents to include on the chip right now.” Additional work is currently being done to further develop the next steps for using PathoChip to identify infectious agents in the clinic. “This will take a great deal more research to eventually lead to approval for frontline clinical use in hospitals,” Robertson said.

This work was supported by an Avon Foundation Grant (Avon-02-2012-053) and by the Abramson Cancer Center Director’s fund.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.


Print version


Media Contact

Karen Kreeger
O: 215-349-5658
C: 215-459-0544

Other Contacts

Department of Communications
(Media Relations):

P: 215-662-2560
F: 215-349-8312

For Patients and the General Public:
Contact Penn Medicine

Media Resources

Contact Us|Facebook
Media Guidelines|Facts
Uplink Facility|Photos
RSS Feeds| Twitter